Committee advances narrower proposal to add GLP‑1 obesity coverage to state employee plan amid fiscal concerns

House Bill 783, sponsored in committee discussion by its sponsor, would expand coverage of GLP‑1 medications in the state employee health plan to include class 3 obesity (BMI ≥40) and polycystic ovary syndrome (PCOS). The bill’s sponsor presented a map showing roughly two dozen states with some GLP‑1 coverage for weight loss and described a significantly lower fiscal estimate in the bill’s current version compared with an earlier draft.

The sponsor walked the committee through differences between fiscal notes: the original fiscal estimate was substantially higher (in the tens of millions) while the current committee amendment’s fiscal estimate was smaller, reflecting narrower eligibility. The sponsor said the expectation underlying the current fiscal note is a 25% increase in cost to the state plan (derived from estimated utilization changes among current GLP‑1 users), though the sponsor said earlier drafts assumed a 10% increase.

Misty Ann Giles, director of the Department of Administration (which runs the state employee plan), rose in opposition on fiscal grounds. Giles said the department could find only nine states that cover GLP‑1s for weight-loss indications and that some states (she cited Colorado) rolled back coverage after costs rose. She warned that the fiscal note still understates the plan’s likely cost exposure and said the bill’s appropriation is one-time and would not cover ongoing costs: “Our big thing here is that this this body chooses to pass it, we need the money. Because my only option is to go and increase employee rates,” she told the committee.

Giles explained the plan’s actuarial assumptions: the department modeled the cost increase by applying an estimated utilization or cost increase against an existing baseline of $6.29 million for diabetes coverage; the department’s actuary projected a 25% cost increase, leaving a projected shortfall in later fiscal years. She said the plan’s current enacted increases were only just sufficient to cover present liabilities and warned of upward pressure on premiums if new benefits are required without additional funding.

Committee members pressed both sponsor and administration staff about wording in the fiscal note. Representative Gillette noted the fiscal note’s phrasing — “expected utilization increase due to expanded coverage eligibility” — and sought clarification whether the language described an increase in people or an increase in cost; both sponsor and director said the department’s actuary intends the figure to represent a projected cost increase, and the sponsor said he would work to revise the fiscal note language.

The sponsor closed by saying the drug class has been available for decades in various indications and that the committee’s amendment narrows the coverage to class 3 obesity and PCOS; he asked members to pass the bill to allow a two‑year pilot and review period. The committee subsequently voted to pass the bill out of committee with an amendment; the roll call recorded 14 yes and 9 no and the bill passed out of committee.